XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.

What to Watch in the Day Ahead - Wednesday, October 30



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>What to Watch in the Day Ahead - Wednesday, October 30</title></head><body>

The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US. Thomson One users can register at RT/DAY/US. All times in ET/GMT

On the U.S. economic front, the Commerce Department's Bureau of Economic Analysis' advance estimate of the gross domestic product (GDP) is expected to show that the economy grew at a 3% pace in the quarter after a similar growth in the previous period. Additionally on Wednesday, the ADP national employment report is expected to show that private employment likely grew by 112,000 jobs in October, after advancing by 143,000 jobs in the month before.


Microsoft is expected to report a rise in quarterly revenue as its Azure cloud business sees strong demand from enterprises doubling down on AI technologies. Investors will be watching for the company's expectations for cloud revenue growth, margin pressures on heavy capital expenditures and progress on monetizing AI.


Analysts expect Facebook-parent Meta Platforms to report an 18% jump in third-quarter revenue. Investors are looking for commentary on how the company plans on further implementing AI technologies in advertising and boosting growth return on investment for advertisers.


Obesity and diabetes drugmaker Eli Lilly will report third-quarter results before markets open. Investors are focused on the performance of its widely used drugs Mounjaro and Zepbound, as well as expansion updates for their manufacturing capacity. Focus will also be on any changes to forecast and updates around its future obesity drug pipeline. Separately, Biogen will report third-quarter results before markets open. Investors will look out for progress on the company's cost-cutting efforts and performance of its newly launched treatments, including Alzheimer's disease drug Leqembi.


Kraft Heinz is expected to post a decline in third-quarter revenue as the packaged food maker faces tepid demand for its snacks and meal kits. Investors will focus on comments around a potential divestiture of its Oscar Mayer business which has attracted bidders and strategies to aid a demand recovery in the U.S.


U.S. oil producer Hess plans to release its third-quarter earnings. The company has agreed to sell itself to Chevron in a $53 billion deal that has been stalled by contract arbitration claims by Exxon Mobil and CNOOC.


AbbVie is scheduled to report its third-quarter earnings before market opens. Investor focus is expected to be on sales of the company's immunology drugs Humira, Skyrizi and Rinvoq. The market may also watch for management commentary on Imbruvica after the U.S. government set the price of the cancer drug for Medicare following negotiations under the Inflation Reduction Act.


Starbucks will announce fourth-quarter results after market close. Following outlook suspension and preliminary results release, investor focus will be on comments from new CEO Brian Niccol on the longer-term strategy to fix issues at the coffee chain.


Robinhood is expected to swing to a profit in Q3 compared to a loss a year ago, bolstered by higher transaction-based revenue.


Global grains merchant Bunge Global will report third-quarter results amid low crop prices and rising supplies available to the company for processing and trading. Investors will be watching for any updates on the company's pending acquisition of grain handler Viterra, a transaction that Bunge had aimed to close by mid-2024 and which has come under antitrust scrutiny in Canada and Europe.

Coinbase is expected to post a third-quarter profit compared to a year-ago loss. Easing regulatory hurdles has facilitated robust trading in the cryptocurrency sector, translating to an increase in the transaction fees of the world's largest crypto exchange.

Health insurer Humana is set to report its third-quarter results before markets open. The focus will be on the company's medical cost ratio, which tracks medical costs and comments on the demand of healthcare services among older adults.

KLA Corp is expected to report higher first-quarter revenue, driven by growing demand for its chipmaking equipment powered by AI boom.


Equinix is expected to report higher third-quarter revenue, as AI boosts demand for its data center services.


DoorDash is expected to post a rise in third-quarter revenue driven by its efforts to expand beyond its restaurant delivery business in the U.S. and into categories such as grocery and alcohol. Investors will look out for comments on delivery costs, new partnerships and a revision to forecasts.


Health and life insurer Aflac is expected to report third-quarter results after markets closed. Investors are expected to look out for premium revenue from its Japan and U.S. units.


MetLife's Q3 profit is expected to jump underpinned by stronger underwriting and higher investment income.


Bleach maker Clorox is expected to post a rise in first-quarter revenue, helped by steady demand for its essentials including cleaning supplies. Investors will look for comments on pricing actions, demand and volumes, impact of input costs and rising competition from private labels as well as annual forecasts.


Online marketplace operator Etsy is expected to post a rise in third-quarter revenue, helped by higher transaction fees and steady demand for handcrafted products at its online marketplace. Investors will look for comments on demand, promotions, discounts, impact from increasing competition from low-cost ecommerce platforms like Temu and annual forecasts.


NiSource is expected to report a fall in third-quarter profit as higher costs weigh on the electric and gas utility. Investors will look out for commentary on agreements with big industrial customers including data center operators.


Verisk Analytics is set to report its third-quarter results. Analysts expect a rise in profit.


Insurer Arch Capital is scheduled to report its third-quarter earnings. Analysts expect lower profits as higher costs offset a massive jump in premiums and investment returns.


CDW is expected to report a rise in quarterly revenue on demand for IT solutions.


On the Latin American front, Mexico's national statistics agency INEGI is scheduled to release the country’s GDP data. For the third quarter, Mexico’s GDP is expected to have grown 0.8% after a 0.2% gain in the previous quarter. On an annual basis, the GDP likely rose 1.2% in the third quarter following a 2.1% growth in the previous period.




Reporting by Indrishka Bose; Editing by Shreya Biswas

</body></html>

වියාචනය: XM Group සමාගම් ක්‍රියාත්මක කිරීම පමණක් වන සේවා සපයන අතර වෙබ් අඩවියේ හෝ වෙබ් අඩවිය හරහා ලබා ගත හැකි අන්තර්ගතය බැලීමට සහ/හෝ භාවිත කිරීමට පුද්ගලයෙකුට ඉඩ සලසමින් අපගේ මාර්ගගත වෙළඳ පහසුකම වෙත ප්‍රවේශය ලබා දෙන අතර වෙනස් කිරීමට හෝ පුළුල් කිරීමට අදහස් නොකරයි. එවැනි ප්‍රවේශය සහ භාවිතය සෑම විටම (i) නියමයන් සහ කොන්දේසි, (ii) අවදානම් අනතුරු ඇඟවීම් සහ (iii) සම්පූර්ණ වියාචනයට යටත් වේ. එබැවින් එවැනි අන්තර්ගතයක් සාමාන්‍ය තොරතුරුවලට වඩා වැඩි යමක් සපයා නොමැත. විශේෂයෙන්ම, අපගේ මාර්ගගත වෙළඳ පහසුකමේ අන්තර්ගතය පෙළඹවීමක් හෝ මූල්‍ය වෙළඳපොළවල කිසිදු ගනුදෙනුවක් සිදු කිරීමට ඉදිරිපත් කිරීමක් නොවන බව කරුණාවෙන් සලකන්න. ඕනෑම මූල්‍ය වෙළඳපොළක වෙළඳාම් කිරීම ඔබේ ප්‍රාග්ධනයට සැලකිය යුතු අවදානමක් එක් කරයි.

අපගේ මාර්ගගත වෙළඳ පහසුකමේ ප්‍රකාශිත සියලු කරුණු අධ්‍යාපනික/තොරතුරුමය අරමුණු සඳහා පමණක් අදහස් කෙරෙන අතර මූල්‍ය, ආයෝජන බදු හෝ වෙළඳ උපදෙස් සහ නිර්දේශයන්; හෝ අපගේ වෙළඳ මිල පිළිබඳ වාර්තාවක්; හෝ ඕනෑම මූල්‍ය උපකරණයක ඉදිරිපත් කිරීමක් හෝ ඒ සඳහා පෙළඹවීමක්; හෝ විශේෂ ඉල්ලීමකින් තොරව ඔබ වෙත ලබා දෙන ලද මූල්‍ය ප්‍රවර්ධනයන් ලෙස නොසැලකිය යුතුය.

ඕනෑම තෙවන පාර්ශවීය අන්තර්ගතයක් මෙන්ම XM විසින් සකසන ලද අන්තර්ගතය එනම් අදහස්, පුවත්, පර්යේෂණ, විශ්ලේෂණ, මිල ගණන් සහ වෙනත් තොරතුරු හෝ මෙම වෙබ් අඩවියේ අන්තර්ගත තෙවන පාර්ශවීය වෙබ් අඩවි සඳහා සබැඳි සාමාන්‍ය වෙළඳපොළ විවරණයක් ලෙස "පවතින පරිදි" සපයා ඇති අතර එහි ආයෝජන උපදෙස් ඇතුළත් නොවේ. ඕනෑම අන්තර්ගතයක් ආයෝජන පර්යේෂණයක් ලෙස අර්ථ දක්වා ඇති ප්‍රමාණයට, ආයෝජන පර්යේෂණයේ ස්වාධීනත්වය ප්‍රවර්ධනය කිරීමට නිර්මාණය කර ඇති නෛතික අවශ්‍යතාවලට අනුකූලව අන්තර්ගතය සකසා නොමැති බවත් එලෙස අරමුණු කර නොමැති බවත් ඔබ සලකා පිළිගත යුතු අතර එබැවින් එය අදාළ නීති සහ රෙගුලාසි යටතේ අලෙවිකරණ සන්නිවේදනයක් ලෙස සලකනු ලැබේ. ඉහත සඳහන් තොරතුරු සලකා මෙතනින් ප්‍රවේශ විය හැකි, ස්වාධීන නොවන ආයෝජන පර්යේෂණ සහ අවදානම් අනතුරු ඇඟවීම පිළිබඳ අපගේ දැනුම්දීම ඔබ කියවා තේරුම් ගෙන ඇති බව සහතික කර ගන්න.

අවදානම් අනතුරු ඇඟවීම: ඔබේ ප්‍රාග්ධනය අවදානමේ පවතී. උත්තෝලිත (ලෙවරේජ්) නිෂ්පාදන සෑම දෙනාටම සුදුසු නොවිය හැකිය. කරුණාකර අපගේ අවදානම් අනාවරණය සලකා බලන්න.